Drones to control capacity
July 8, 2021
Lightweight sprayed materials for reinforcing and rehabilitating urban heritage buildings and structures
July 15, 2021inLab FIB is collaborating with the company ABAC Therapeutics (ABAC) to develop a drug discovery platform to identify new antibiotics designed to combat multidrug-resistant bacteria.
ABAC Therapeutics is a company that investigates new antibiotics for certain pathogens and develops treatment solutions against multiantibiotic-resistant bacteria. ABAC uses its own drug discovery platform PasNas to identify new antibiotics designed to combat multidrug-resistant bacteria for patients infected with bacterial pathogens that are highly resistant to antibiotics that leave patients affected with few (or no) treatment options. This new strategy enables the identification of compounds with specific activity and new mechanisms of action that do not harm human bacterial flora and minimise the selection of resistant strains.
inLab FIB is in charge of developing the computer platform that supports the analysis of data from experimental processes.
The project has been developed in two periods: an initial period from July 2018 to January 2019 and an extension of the project from July 2020 until December 2021.
Technology
Topic
You want to know more?
Related Projects
- 30/09/2024Project Headerrightno-repeat;left top;;auto20px A team from the Centre for Research in Biomedical Engineering (CREB) of the UPC and Sant Joan de Déu has created a new […]
- Barcelona is characterised by a high consumption of bottled water (55% of the population drinks it regularly). The reasons for this behaviour tend to be dissatisfaction with the organoleptic characteristics, perceived health risks and distrust of the quality of tap water.
- The research groups Soft Computing Research Group (SOCO) and Knowledge Engineering Research Group (GREC) at UPC are developing a personalised medicine platform to improve psychological treatment for psychosis. Using predictive models, the tool will foresee the effectiveness of therapy to tailor treatment. The prototype will be tested in a year-long clinical trial with patients worldwide.
- The Radio Frequency Identification and Flexible Electronics (RFLEX) group of the Universitat Politècnica de Catalunya - BarcelonaTech (UPC) is participating in the TELEBREATH project to better address the demand for long-term care in vulnerable groups, such as elderly and dependent people.
